7.250USD+1.33%Mkt Cap: 444.00M USDP/E: —Last update: 2026-06-01
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fi…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap444.00M USD
Enterprise Value345.67M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-51.04M USD
Revenue/Share—
Last Price7.250 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees16
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-5.56
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B2.32
EPS (TTM)-1.35
EPS (Forward)-1.31
52W Range
3.32049% of range11.41
52W High11.41 USD
52W Low3.320 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-45.82%
ROA-43.82%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-45.65M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-6.21%
Net Debt-104.50M USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity0.00
Current Ratio20.34
Quick Ratio19.74
Book Value/Sh3.144 USD
Cash/Share1.693 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)26.20 USD
Target Range8.000 USD – 49.00 USD
# Analysts10
Ownership
Shares Out.61.18M
Float59.14M
Insiders3.50%
Institutions21.93%
Short Interest
Short Ratio1.4d
Short % Float6.94%
Short % Out.6.82%
Shares Short4.21M
Short (prev mo.)3.60M
Technical
SMA 506.431 (+12.7%)
SMA 2006.609 (+9.7%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)2.57M
Avg Vol (10d)833.89K
Technical Indicators
RSI (14)51.6
MACD0.1227
MACD Signal0.1885
MACD Hist.-0.0658
BB Upper8.294 USD
BB Middle7.362 USD
BB Lower6.431 USD
BB Width25.31%
ATR (14)0.5077 USD
Vol Ratio (20d)0.28x